Receptor-mediated tumor targeting based on peptide hormones.
BACKGROUND
Tumor targeting with peptides is based on the discovery that receptors for many regulatory peptides are overexpressed in tumor cells, compared with their expression in normal tissues. Consequently, these peptides and their analogues can be used as carriers/targeting moieties for the preparation of diagnostic and therapeutic agents that have increased selectivity and decreased peripheral toxicity.


METHODS
Here an overview is given of the most relevant gonadotropin-releasing hormone (GnRH) and somatostatin derivatives, as well as of their applications in cancer diagnosis and therapy. For this purpose, recently published data in these areas (mostly articles published from 2000 to 2009) were reviewed.


RESULTS
In contrast to other regulatory peptides that stimulate the tumor growth, GnRH and somatostatin derivatives have inhibitory effect; therefore, they were used primarily for the preparation of various conjugates to be used in targeted chemotherapy, targeted radiotherapy, photodynamic therapy, boron neutron capture therapy and cancer diagnosis. Some of these conjugates have already found clinical applications, whereas others are now in preclinical and clinical trials.


CONCLUSIONS
Tumor targeting with hormone peptides provides a basis for the development of new diagnostic and therapeutic approaches for cancer.
Mezo
Gábor
G
Eötvös Loránd University, Research Group of Peptide Chemistry, Hungarian Academy of Sciences, 1117 Budapest, Hungary. gmezo@elte.hu
Manea
Marilena
M
D045744:Cell Line, Tumor; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D010455:Peptides / Q000627:therapeutic use*; D011966:Receptors, LHRH / Q000378:metabolism
D006728:Hormones; D010455:Peptides; D011966:Receptors, LHRH